Chronic

Novartis Rhapsido® receives European Fee approval as first oral focused remedy for power spontaneous urticaria 
Press Releases

Novartis Rhapsido® receives European Fee approval as first oral focused remedy for power spontaneous urticaria 

Dupixent® (dupilumab) Authorized within the U.S. because the First Biologic Drugs for Younger Youngsters with Uncontrolled Persistent Spontaneous Urticaria (CSU)
Partnerships

Dupixent® (dupilumab) Authorized within the U.S. because the First Biologic Drugs for Younger Youngsters with Uncontrolled Persistent Spontaneous Urticaria (CSU)

Pruritus Therapeutics Market Measurement is Projected to Attain USD 15.58 Billion by 2035 Because of the Growing Instances of Persistent Inflammatory Pores and skin Ailments Globally | SNS Insider
Press Releases

Pruritus Therapeutics Market Measurement is Projected to Attain USD 15.58 Billion by 2035 Because of the Growing Instances of Persistent Inflammatory Pores and skin Ailments Globally | SNS Insider